<DOC>
	<DOC>NCT00637286</DOC>
	<brief_summary>The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months</brief_summary>
	<brief_title>ZAP, US. Zomig for Appropriate for Primary Care</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Have an established diagnose of migraine as with an age at onset of less than 50 years Have experienced an average of at least 1 migraine headache per month in the previous three months Be able to differentiate between migraine and nonmigraine headaches Use of any triptan within the last 12 months or use of MAOA inhibitors, methysergide or methylergonovine in the 2 weeks before entering the study. History of basilar, ophthalmoplegic or hemiplegic migraine headache or any potentially serious neurological condition that is associated with headache History, symptoms, or significant risk factors for ischaemic heart or other cardiovascular disease, including coronary vasospasm, cardiac accessory conduction pathways or arrhythmias or uncontrolled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Zolmitriptan</keyword>
	<keyword>ZOMIG</keyword>
	<keyword>migraine</keyword>
	<keyword>headache response</keyword>
	<keyword>headache</keyword>
	<keyword>headache pain</keyword>
	<keyword>MIDAS</keyword>
	<keyword>HCPC</keyword>
</DOC>